Szczurek Paulina, Mosiichuk Nadia, Woliński Jarosław, Yatsenko Tetiana, Grujic Danica, Lozinska Liudmyla, Pieszka Marek, Święch Ewa, Pierzynowski Stefan Grzegorz, Goncharova Kateryna
Department of Biology, Lund University, Lund, Sweden.
Department of Animal Nutrition and Feed Sciences, National Research Institute of Animal Production, Balice, Poland.
PLoS One. 2017 Jun 8;12(6):e0179195. doi: 10.1371/journal.pone.0179195. eCollection 2017.
An elevated level of serum uric acid-hyperuricemia, is strongly associated with the development of gout and chronic kidney disease (CKD) which is often accompanied by a significantly reduced glomerular filtration rate (GFR). In the present study, we investigated the extra-renal elimination of uric acid via the intestine in a healthy pig model and the effect of oral uricase therapy on plasma uric acid concentrations in pigs with induced hyperuricemia and CKD. The experiment was conducted on eleven, ten-week-old pigs (n = 11). The porcine model of CKD was developed by performing 9/10 nephrectomy surgery on eight pigs. A stable model of hyperuricemia was established in only five of the eight nephrectomized pigs by frequent injections of uric acid (UA) into the jugular vein. All pigs (three healthy pigs and five CKD pigs) were operated for implantation of jugular vein catheters and the three healthy pigs also had portal vein catheters inserted. Blood uric acid concentrations were measured spectrophotometrically, using the Uric Acid Assay Kit (BioAssay Systems, Hayward, USA). The piglets with CKD received orally administered uricase (treatment) and served as their own controls (without uricase supplementation). Oral uricase therapy significantly decreased plasma uric acid concentrations in pigs with CKD, whereas hyperuricemia was observed in the pigs whilst not being treated with uricase. Urinary uric acid excretion was similar during both the treatment and control periods during the first 8 h and 24 h after UA infusions in the CKD pigs. To demonstrate the elimination of UA via the intestine, the healthy pigs were infused with UA into the jugular vein. The blood collected from the jugular vein represents circulating UA concentrations and the blood collected from the portal vein represents the concentration of UA leaving the intestine. The final (after 2 h) concentration of UA was significantly lower in blood collected from the portal vein compared to that collected from the jugular vein (3.34 vs. 2.43 mg/dL, respectively, p = 0.024). The latter allows us to suggest that UA is eliminated from the blood via the gut tissue.
血清尿酸水平升高——高尿酸血症,与痛风和慢性肾脏病(CKD)的发生密切相关,慢性肾脏病常伴有肾小球滤过率(GFR)显著降低。在本研究中,我们在健康猪模型中研究了尿酸通过肠道的肾外排泄情况,以及口服尿酸酶疗法对诱导性高尿酸血症和慢性肾脏病猪血浆尿酸浓度的影响。实验在11头10周龄的猪(n = 11)身上进行。通过对8头猪实施9/10肾切除术建立慢性肾脏病猪模型。在8头接受肾切除的猪中,只有5头通过频繁向颈静脉注射尿酸(UA)建立了稳定的高尿酸血症模型。所有猪(3头健康猪和5头慢性肾脏病猪)均接受手术植入颈静脉导管,3头健康猪还插入了门静脉导管。使用尿酸检测试剂盒(美国海沃德市生物检测系统公司)通过分光光度法测量血尿酸浓度。患有慢性肾脏病的仔猪口服尿酸酶(治疗组)并作为自身对照(未补充尿酸酶)。口服尿酸酶疗法显著降低了慢性肾脏病猪的血浆尿酸浓度,而未用尿酸酶治疗的猪则出现高尿酸血症。在慢性肾脏病猪输注尿酸后的前8小时和24小时内,治疗期和对照期的尿尿酸排泄相似。为了证明尿酸通过肠道的排泄情况,向健康猪的颈静脉输注尿酸。从颈静脉采集的血液代表循环中的尿酸浓度,从门静脉采集的血液代表离开肠道的尿酸浓度。门静脉采集的血液中尿酸的最终(2小时后)浓度显著低于颈静脉采集的血液(分别为3.34 vs. 2.43 mg/dL,p = 0.024)。后者使我们认为尿酸通过肠道组织从血液中排出。